title: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach.
abstract: Anti-angiogenic agents are biological drugs used for treatment of retinal neovascular degenerative diseases. In this study, we aimed at in silico analysis of interaction of vascular endothelial growth factor A (VEGFA), the main mediator of angiogenesis, with binding domains of anti-angiogenic agents used for treatment of retinal diseases, such as ranibizumab, bevacizumab and aflibercept. The analysis of anti-VEGF/VEGFA complexes was carried out by means of protein-protein docking and molecular dynamics (MD) coupled to molecular mechanics-Poisson Boltzmann Surface Area (MM-PBSA) calculation. Molecular dynamics simulation was further analyzed by protein contact networks. Rough energetic evaluation with protein-protein docking scores revealed that aflibercept/VEGFA complex was characterized by electrostatic stabilization, whereas ranibizumab and bevacizumab complexes were stabilized by Van der Waals (VdW) energy term; these results were confirmed by MM-PBSA. Comparison of MM-PBSA predicted energy terms with experimental binding parameters reported in literature indicated that the high association rate (Kon) of aflibercept to VEGFA was consistent with high stabilizing electrostatic energy. On the other hand, the relatively low experimental dissociation rate (Koff) of ranibizumab may be attributed to lower conformational fluctuations of the ranibizumab/VEGFA complex, higher number of contacts and hydrogen bonds in comparison to bevacizumab and aflibercept. Thus, the anti-angiogenic agents have been found to be considerably different both in terms of molecular interactions and stabilizing energy. Characterization of such features can improve the design of novel biological drugs potentially useful in clinical practice.
authors.affiliation: Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania Catania, Italy.
authors.forename: Chiara B M
authors.initials: CB
authors.lastname: Platania
authors.affiliation: School of Engineering, University Campus BioMedico Roma, Italy.
authors.forename: Luisa
authors.initials: L
authors.lastname: Di Paola
authors.affiliation: Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania Catania, Italy.
authors.forename: Gian M
authors.initials: GM
authors.lastname: Leggio
authors.affiliation: Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania Catania, Italy.
authors.forename: Giovanni L
authors.initials: GL
authors.lastname: Romano
authors.affiliation: Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania Catania, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: Drago
authors.affiliation: Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania Catania, Italy.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Salomone
authors.affiliation: Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania Catania, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Bucolo
keywords: aflibercept; bevacizumab; diabetic retinopathy; molecular dynamics; ranibizumab